Related Experiment Video

Updated: Nov 23, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.9K

Chlamydia muridarum Alleviates Colitis via the IL-22/Occludin Signal Pathway

Xin Wang1,2, Huai-Cai Zeng1, Yan-Ru Huang2

  • 1School of Biotechnology, Guilin Medical University, Guilin 541199, China.

Biomed Research International
|December 31, 2020
PubMed

Insights

Chlamydia muridarum ameliorates ulcerative colitis symptoms by enhancing the IL-22/occludin pathway. This study reveals a novel therapeutic mechanism for inflammatory bowel disease involving gut microbiota modulation.

Area of Science:

  • Microbiology
  • Gastroenterology
  • Immunology

Background:

  • Ulcerative colitis (UC) is a prevalent inflammatory bowel disease with increasing incidence.
  • Gut microbiota is implicated in UC pathogenesis, but specific bacterial effects are unclear.
  • Chlamydia species colonize the gastrointestinal tract without obvious pathogenicity.

Purpose of the Study:

  • To investigate the effects of Chlamydia muridarum (C. muridarum) on dextran sodium sulfate (DSS)-induced colitis.
  • To elucidate the molecular mechanisms underlying C. muridarum's impact on colitis.

Main Methods:

  • Induction of colitis in a mouse model using DSS.
  • Administration of C. muridarum to DSS-treated mice.
  • Assessment of colitis severity, colon length, and histopathology.
  • Measurement of interleukin-22 (IL-22) and occludin expression levels.

Main Results:

  • C. muridarum significantly improved colitis symptoms, including weight loss and disease activity.
  • C. muridarum administration restored reduced colonic expression of IL-22 and occludin caused by DSS.
  • IL-22 was essential for C. muridarum's ameliorative effects on colitis and occludin levels.

Conclusions:

  • C. muridarum ameliorates DSS-induced ulcerative colitis.
  • The therapeutic effect is mediated through the IL-22/occludin signaling pathway.
  • C. muridarum represents a potential therapeutic agent for ulcerative colitis.

More Related Videos

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.3K
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

17.1K

Related Concept Videos

Bacterial Phylum Chlamydiae01:29

Bacterial Phylum Chlamydiae

The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic...
254
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
638
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
320
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
327
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
580